Literature DB >> 35581525

KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1.

Xiaofeng Han1, Jie Chen2.   

Abstract

Lysine acetyltransferase 2 A (KAT2A) has been implicated in tumorigenesis; nevertheless, the mechanism underlying its tumor-initiating effect remains elusive. In the present study, we aimed to identify the possible role of KAT2A in regulating metabolic reprogramming, a hallmark of cancer, in colon cancer (CC). KAT2A was found to be overexpressed in CC and correlated with metastases. KAT2A induced proliferation, migration, invasion, and epithelial-mesenchymal transition of CC cells, along with elevated cellular glycolytic capacity and mitochondrial stress. Functional enrichment analyses predicted and ChIP assays verified that KAT2A activated E2F transcription factor 1 (E2F1) by modifying the acetylation of H3K9. Rescue experiments revealed that E2F1 downregulation inhibited cellular activity, aerobic glycolysis and mitochondrial respiration in CC in the presence of KAT2A. Moreover, KAT2A/E2F1 promoted tumorigenic activity and lung metastases of CC cells in mice. Taken together, our findings demonstrate the substantial role of KAT2A in the modulation of post-translational modifications of E2F1 in CC, suggesting that knockdown of KAT2A may be a potential strategy for CC treatment.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  Colon cancer; E2F1; KAT2A; Metastases; The Warburg effect

Mesh:

Year:  2022        PMID: 35581525     DOI: 10.1007/s13577-022-00707-3

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  27 in total

1.  KAT2A succinyltransferase activity-mediated 14-3-3ζ upregulation promotes β-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells.

Authors:  Yingying Tong; Dong Guo; Dong Yan; Chunmin Ma; Fei Shao; Yugang Wang; Shudi Luo; Liming Lin; Jingjing Tao; Yuhui Jiang; Zhimin Lu; Dongming Xing
Journal:  Cancer Lett       Date:  2019-10-11       Impact factor: 8.679

2.  Colorectal cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-03-05       Impact factor: 508.702

3.  NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.

Authors:  Zejun Fang; Chaoju Gong; Songshan Yu; Weihua Zhou; Waseem Hassan; Hongzhang Li; Xue Wang; Yanyan Hu; Kaipeng Gu; Xixi Chen; Bing Hong; Yuyan Bao; Xiang Chen; Xiaomin Zhang; Hong Liu
Journal:  Cancer Lett       Date:  2017-12-22       Impact factor: 8.679

Review 4.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Athanasios Xanthoulis; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

5.  LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.

Authors:  Mengxin Lin; Meifang Xu; Zongbin Xu; Zongqi Weng; Bingqiang Lin; Yanqin Lan; Qing Liu; Xiaoyan Lin; Jie Pan
Journal:  Hum Cell       Date:  2021-04-06       Impact factor: 4.174

Review 6.  Regulation of chromatin and gene expression by metabolic enzymes and metabolites.

Authors:  Xinjian Li; Gabor Egervari; Yugang Wang; Shelley L Berger; Zhimin Lu
Journal:  Nat Rev Mol Cell Biol       Date:  2018-09       Impact factor: 94.444

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Tissue metabolic profiling reveals major metabolic alteration in colorectal cancer.

Authors:  Yao Shen; Mao Sun; Jun Zhu; Mengying Wei; Huichen Li; Pan Zhao; Jiajia Wang; Ruikai Li; Lianlian Tian; Yanyan Tao; Peng Shen; Jian Zhang
Journal:  Mol Omics       Date:  2021-06-14

9.  LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1.

Authors:  Stella Logotheti; Stephan Marquardt; Shailendra K Gupta; Christin Richter; Berdien A H Edelhäuser; David Engelmann; Julia Brenmoehl; Christoph Söhnchen; Nico Murr; Michael Alpers; Krishna P Singh; Olaf Wolkenhauer; Dirk Heckl; Alf Spitschak; Brigitte M Pützer
Journal:  Theranostics       Date:  2020-07-29       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.